Anthera Provides Business Update And Reports 2016 First Quarter Financial Results
- SOLUTION clinical study of Sollpura™ expanded to Europe, Israel and Canada in addition to ongoing US enrollment
- Craig Thompson named as President and Chief Operating Officer
- Appointment of Dr. James Pennington to Interim Chief Medical Officer
- Enrollment of BRIGHT-SC Phase 2 clinical study in IgA Nephropathy completed
- Bulk manufacturing campaign for blisibimod completed for CHABLIS-7.5
HAYWARD, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today provided a business update and reported financial results for the first quarter ended March 31, 2016.
Recent Developments and Business Highlights:
Sollpura™ (liprotamase) – Exocrine Pancreatic Insufficiency
- Phase 3 SOLUTION Clinical Study Enrollment open in Europe
In the first quarter of 2016, we continued further clinical site activation for the Phase 3 SOLUTION clinical study to include four European countries, Israel and Canada. This study evaluates the efficacy and safety of the capsule formulation of Sollpura™ to treat exocrine pancreatic insufficiency in patients with cystic fibrosis. - SIMPLICITY Clinical Study expected to begin enrollment in Q2 2016
The SIMPLICITY clinical study will be the first to offer Sollpura™ supplied in a convenient, easy-to-administer packet, which can be mixed with water or apple juice for drinkable dose administration. After an initial cohort of patients older than 7, this study will allow for administration of Sollpura™ powder for oral solution to pediatric patients ranging in age from 28 days to seven years. For more information on the study, visit http://www.anthera.com/clinical-studies/simplicity-study/.